相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Letter
Immunology
Pragya D. Yadav et al.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Shengli Xia et al.
Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.
LANCET INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Jessica A. Plante et al.
Summary: The D614G substitution in the SARS-CoV-2 spike protein enhances viral replication and infectivity in human lung epithelial cells, primary airway tissues, and hamsters. This variant may increase transmission in the upper respiratory tract and doesn't seem to significantly reduce vaccine efficacy. Further research on therapeutic antibodies targeting the circulating G614 virus is recommended.
Review
Microbiology
Ben Hu et al.
Summary: This review summarizes the research progress on SARS-CoV-2 and COVID-19, including virology characteristics, pathogenesis, and recent advances in treatment methods. Furthermore, it discusses in detail the potential wildlife hosts and zoonotic origin of this emerging virus.
NATURE REVIEWS MICROBIOLOGY
(2021)
Article
Microbiology
Allison J. Greaney et al.
Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.
CELL HOST & MICROBE
(2021)
Article
Microbiology
Drew Weissman et al.
Summary: The D614G mutation in the spike protein of SARS-CoV-2 is not expected to hinder current vaccine development, as viruses with the G614 spike are more susceptible to neutralization, indicating that the mutation may not affect vaccine efficacy.
CELL HOST & MICROBE
(2021)
Article
Cell Biology
Hangping Yao et al.
Summary: This study developed a therapeutic antibody cocktail against SARS-CoV-2 by exploiting antibody cooperativity, consisting of two antibodies that achieved synergistic neutralization through S1 shielding and conformational locking, blocking receptor attachment and viral membrane fusion to combat viral mutation escape. Additionally, a hypothetical third antibody partner was identified for further reinforcement as pan-SARS-CoVs therapeutics.
Article
Multidisciplinary Sciences
Christian Gaebler et al.
Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.
News Item
Multidisciplinary Sciences
Kai Kupferschmidt
Article
Multidisciplinary Sciences
Tyler N. Starr et al.
Summary: Research has found that mutations in the receptor binding domain (RBD) of SARS-CoV-2 may potentially escape the action of the REGN-COV2 cocktail, providing important information for interpreting mutations observed during viral surveillance.
Article
Virology
Charles B. Stauft et al.
Summary: By infecting hamsters with two variants of SARS-CoV-2, this study found that there was no significant difference in pathogenicity between the naturally circulating D614 and G614 variants.
Article
Multidisciplinary Sciences
Zhiqiang Ku et al.
Summary: Antibody cocktails are a promising approach to prevent SARS-CoV-2 escape, with a combination of antibodies CoV2-06 and CoV2-14 identified as effective in preventing viral escape and providing protection in mice, offering new insights for treating COVID-19.
NATURE COMMUNICATIONS
(2021)
News Item
Medicine, General & Internal
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Public, Environmental & Occupational Health
Summer E. Galloway et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Review
Pharmacology & Pharmacy
Jeroen Pollet et al.
Summary: This article points out that recombinant protein vaccines may become a favorable option in the context of the COVID-19 pandemic, despite being overlooked in early development, they may offer an advantage or complement under the current circumstances.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Article
Biochemistry & Molecular Biology
Qianqian Li et al.
Summary: The 501Y.V2 variants of SARS-CoV-2 with multiple mutations are rapidly spreading from South Africa to other countries, showing reduced susceptibility to neutralizing antibodies and potential compromise of monoclonal antibodies and vaccines. Enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of transmission to mice.
Article
Biochemistry & Molecular Biology
Piyada Supasa et al.
Summary: Research on the UK-dominant variant B.1.1.7 shows that it is harder to neutralize than the parental virus, but widespread escape from antibodies or monoclonal antibodies has not been observed yet.
Article
Biochemistry & Molecular Biology
Emma C. Thomson et al.
Summary: SARS-CoV-2 virus can mutate and evade immunity, with mutations like N439K conferring resistance against neutralizing monoclonal antibodies and enhancing binding affinity to hACE2 receptor. Despite similar in vitro replication fitness and clinical outcomes compared to wild type, N439K mutation highlights the importance of ongoing molecular surveillance for guiding vaccine and therapeutic development and usage.
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.
Article
Biochemistry & Molecular Biology
Daming Zhou et al.
Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Article
Microbiology
Xiaoying Shen et al.
Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.
CELL HOST & MICROBE
(2021)
Article
Microbiology
Zhuoming Liu et al.
Summary: The study found that antibodies targeting the SARS-CoV-2 spike protein have escape mutations, different monoclonal antibodies have unique resistance profiles, some mutants are resistant to multiple antibodies while some variants can escape neutralization by convalescent sera. Comparing antibody-mediated mutations with circulating SARS-CoV-2 sequences revealed substitutions that may weaken neutralizing immune responses in some individuals, warranting further investigation.
CELL HOST & MICROBE
(2021)
Article
Microbiology
Allison J. Greaney et al.
Summary: The evolution of SARS-CoV-2 may impact the recognition of the virus by human antibody-mediated immunity, with mutations affecting antibody binding varying significantly among individuals and within the same individual over time. Despite this variability, mutations that greatly reduce antibody binding usually occur at specific sites in the RBD, with E484 being the most crucial. These findings can inform surveillance efforts for SARS-CoV-2 evolution in the future.
CELL HOST & MICROBE
(2021)
Letter
Medicine, General & Internal
Wenjuan Zhang et al.
Summary: The research focused on sequencing and phylogenetic analyses of SARS-CoV-2 isolates from symptomatic patients at Cedar-Sinai Medical Center in November-December 2020, providing insights into a surge in cases and hospitalizations during that period.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Editorial Material
Medicine, General & Internal
Ester C. Sabino et al.
Article
Multidisciplinary Sciences
Dami A. Collier et al.
Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.
Article
Multidisciplinary Sciences
Houriiyah Tegally et al.
Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.
Article
Multidisciplinary Sciences
Steven A. Kemp et al.
Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.
Article
Biochemistry & Molecular Biology
Constantinos Kurt Wibmer et al.
Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Kai Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Yang Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.
Article
Multidisciplinary Sciences
Katrina A. Lythgoe et al.
Summary: The study found that SARS-CoV-2 infections in clinical samples in the UK are characterized by low levels of within-host diversity and a narrow bottleneck at transmission. Most variants are either lost or occasionally fixed at the point of transmission, with shared diversity not persisting.
Article
Multidisciplinary Sciences
Chadi M. Saad-Roy et al.
Summary: Given vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to SARS-CoV-2. While focusing on one dose may decrease infections in the short term, the long-term outcomes depend on the relative immune robustness of this approach. Under conditions of partial population immunity, a one-dose policy may increase the potential for antigenic evolution.
Article
Multidisciplinary Sciences
Kevin R. McCarthy et al.
Summary: The translation above discusses zoonotic pandemics caused by animal viruses spilling over into highly susceptible human populations, specifically focusing on the evolution of coronaviruses in human hosts and the impact of recurrent deletions in the spike glycoprotein on antibody epitopes. These studies help understand the antigenic evolution and adaptive evolution of SARS-CoV-2.
Article
Multidisciplinary Sciences
Alexander Muik et al.
Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.
Article
Multidisciplinary Sciences
Yunkai Zhu et al.
Summary: The SARS-CoV-2 spike protein contains a multi-basic cleavage site that affects virus entry and transmission, as shown in hamster models. Host factors affecting virus entry were identified through a genome-wide CRISPR screen.
NATURE COMMUNICATIONS
(2021)
News Item
Medicine, General & Internal
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL
(2021)
News Item
Medicine, General & Internal
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Tara Alpert et al.
Summary: The study found that the SARS-CoV-2 B.1.1.7 variant primarily spread in the United States through ports of entry in New York, California, and Florida, with multiple independent establishments starting in early December 2020 and interstate spread by the end of the month. It is projected that B.1.1.7 will become the dominant lineage in many states by mid- to late March, highlighting the urgent need to enhance genomic surveillance.
Article
Biochemistry & Molecular Biology
Matthew McCallum et al.
Summary: The study identifies 41 human monoclonal antibodies that recognize the N-terminal domain of the SARS-CoV-2 spike protein and exhibit strong neutralizing activity. These antibodies inhibit cell-to-cell fusion, activate effector functions, and protect animals from virus challenge, highlighting the importance of NTD-specific neutralizing antibodies for protective immunity and vaccine development. Several SARS-CoV-2 variants with mutations in the NTD supersite suggest ongoing selective pressure on the virus.
Article
Biochemistry & Molecular Biology
Meghan E. Garrett et al.
Summary: This study used the Phage-DMS approach to define antibody escape profiles to the SARS-CoV-2 S protein in COVID-19 convalescent plasma. It found common antibody binding regions but variable escape mutations within these regions, as well as individual variation in less commonly targeted epitopes. This suggests potential individual variation in antibody-mediated virus evolution.
Article
Biochemistry & Molecular Biology
Xianding Deng et al.
Summary: A new SARS-CoV-2 variant named B.1.427/B.1.429 was identified in California, with increased transmissibility and carrying three mutations in spike protein, including L452R substitution. The variant emerged in May 2020 and became predominant in sequenced cases from September 2020 to January 2021. In vivo viral shedding was increased and antibody neutralization decreased, calling for further investigation.
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: Ending the SARS-CoV-2 pandemic requires global vaccination. New virus strains with mutations impact antibody responses, but some variants are less resistant than others. A monoclonal antibody can neutralize different variants and partially restore neutralization potency for other public antibodies.
Editorial Material
Infectious Diseases
Antonino Di Caro et al.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Immunology
Carl Graham et al.
Summary: The interaction between the SARS-CoV-2 Spike receptor binding domain (RBD) and the host cell receptor ACE2 is crucial for viral entry, with RBD being the main target for neutralizing antibodies. Mutations in RBD, N-terminal domain (NTD), and S2 subunits of Spike have been found in circulating SARS-CoV-2 variants. This study isolates and characterizes monoclonal antibodies targeting different epitopes on RBD, NTD, and S2 to understand how these mutations affect antigenicity and neutralization resistance.
Article
Virology
Felicidade Pereira et al.
Summary: The emergence of new variants of SARS-CoV-2 has posed challenges for public health authorities in tracking transmission and mitigating the impact of the pandemic. The B.1.525 variant, with genetic signatures from P.1, B.1.1.7, and B.1.351, has been identified in a traveler returning from Nigeria, highlighting the need for continued vigilance in monitoring and controlling the spread of the virus.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Medicine, General & Internal
Katherine R. W. Emary et al.
Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.
Article
Infectious Diseases
Shilong Yang et al.
Summary: The results from Phase 1 and Phase 2 trials of the COVID-19 vaccine ZF2001 show that the vaccine is well tolerated and immunogenic, supporting the use of a 25 microgram dose in a three-dose schedule for large-scale evaluation in a Phase 3 trial.
LANCET INFECTIOUS DISEASES
(2021)
Letter
Infectious Diseases
Muthukumar Ramanathan et al.
LANCET INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Kevin O. Saunders et al.
Summary: This study demonstrates that immunizing macaques with nanoparticles conjugated with the receptor-binding domain of SARS-CoV-2, adjuvanted with 3M-052 and alum, can elicit cross-neutralizing antibody responses against various coronaviruses and provide protection against SARS-CoV-2. Nucleoside-modified mRNAs encoding stabilized spike proteins also induce antibody responses against different coronaviruses, suggesting potential for developing vaccines against multiple betacoronaviruses in the future.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study compared the neutralization of non-VOC and 501Y.V2 VOC variants using plasma from COVID-19 patients in South Africa. It found that plasma from individuals infected during the first wave effectively neutralized the first-wave virus variant, while plasma from those infected in the second wave effectively neutralized the 501Y.V2 variant.
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: Studies have shown that the SARS-CoV-2 B.1.1.7 lineage is more transmissible and may cause more severe illness compared to pre-existing variants.
Article
Multidisciplinary Sciences
Erik Volz et al.
Summary: Genetic and testing data from England indicate that the SARS-CoV-2 variant B.1.1.7 has a transmission advantage over other lineages, showing a rapid expansion during autumn 2020. Analysis of S gene target failures (SGTF) in community-based diagnostic PCR testing suggests that B.1.1.7 is more transmissible than non-variant of concern lineages and has a significant transmission advantage, with a reproduction number 50% to 100% higher. Additionally, cases of B.1.1.7 appear to include a larger share of under 20-year-olds compared to non-variant cases.
Letter
Medicine, General & Internal
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Guo-Lin Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Kathleen M. Neuzil
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. A. Madhi et al.
Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Nicole Doria-Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Multidisciplinary Sciences
Jon Cohen
Summary: Researchers are working on developing vaccines that can protect against multiple coronaviruses at once, aiming to enhance immunity against future coronavirus infectious diseases.
Article
Multidisciplinary Sciences
Nuno R. Faria et al.
Summary: A new variant of concern, P.1, with 17 mutations including three spike protein mutations associated with increased binding to human ACE2 receptors, emerged in Manaus, Brazil between November 2020 and January 2021. Molecular analysis suggests P.1 may be 1.7- to 2.4-fold more transmissible and that previous infection may provide 54 to 79% protection against P.1 infection compared to other lineages. Enhanced global genomic surveillance of such variants is crucial for pandemic response.
Article
Public, Environmental & Occupational Health
Corinne N. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Biochemistry & Molecular Biology
Chang Liu et al.
Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.
Letter
Medicine, General & Internal
Emma C. Wall et al.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.
Review
Microbiology
William T. Harvey et al.
Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.
NATURE REVIEWS MICROBIOLOGY
(2021)
Article
Multidisciplinary Sciences
Emanuele Andreano et al.
Summary: Research suggests that SARS-CoV-2 has the potential to generate variants resistant to neutralizing antibodies, and computational modeling predicts that these variants may prevent binding of neutralizing antibodies. Therefore, the development of vaccines and antibodies capable of controlling emerging variants is crucial.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Multidisciplinary Sciences
Lingshu Wang et al.
Summary: The study identified four receptor binding domain-targeting antibodies with potent neutralizing activity against 23 variants, including two ultrapotent antibodies. Combinations of these antibodies reduced the in vitro generation of escape mutants, showing potential in mitigating resistance development.
Article
Multidisciplinary Sciences
Meng Yuan et al.
Summary: Mutations in the RBS residues of new variant strains of the coronavirus can affect the binding and neutralizing effects of antibodies, but have little impact on antibodies targeting more conserved neutralizing sites.
Article
Multidisciplinary Sciences
Matthew McCallum et al.
Summary: The novel CAL.20C (B.1.427/B.1.429) variant carries spike protein mutations, resulting in reduced neutralizing titers in vaccinated individuals and convalescent individuals. The L452R mutation reduces neutralizing activity in RBD-specific monoclonal antibodies, while the S13I and W152C mutations lead to the total loss of neutralization in NTD-specific antibodies due to antigenic supersite remodeling.
Article
Multidisciplinary Sciences
Amarendra Pegu et al.
Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.
Article
Microbiology
Hao Zhou et al.
Summary: A new SARS-CoV-2 variant B.1.526 has been identified in New York City and is spreading rapidly, but current evidence suggests that vaccine-elicited antibodies and Regeneron therapeutic monoclonal antibodies remain effective in combating the B.1.526 variant.
Article
Multidisciplinary Sciences
Anthony P. West et al.
Summary: Wide-scale SARS-CoV-2 genome sequencing is crucial for tracking viral evolution. The software tool Variant Database was developed to quickly examine spike mutations, and the emergence and spread of the B.1.526 lineage in New York has extended the second wave of COVID-19 cases.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Allison J. Greaney et al.
Summary: The study found that although the human immune system can produce antibodies that target diverse RBD epitopes, in practice, the polyclonal response to infection tends to be skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Elaine C. Chen et al.
Summary: Unrelated individuals can produce genetically similar clones of antibodies known as public clonotypes, which have been identified in responses to different infectious diseases and in healthy individuals. By studying memory B cells from convalescent survivors of SARS-CoV-2 infection and plasmablasts from vaccinated individuals, researchers have identified 29 public clonotypes with potential neutralizing abilities against the virus. These findings provide insight into the molecular mechanisms behind the efficacy of SARS-CoV-2 vaccines and reveal the immune pressures influencing the selection of common viral escape mutants.
Article
Cell Biology
Bo Meng et al.
Summary: The Delta H69N70 mutation in SARS-CoV-2 spike protein increases infectivity and partially rescues immune escape mutations that impair infectivity. Continued surveillance and research on deletions with functional effects are necessary.
Article
Cell Biology
Yongbing Pan et al.
Summary: This study isolated ten neutralizing antibodies from the immune cells of COVID-19 convalescent patients, with 2B11 showing the highest affinity and neutralization potency against the original SARS-CoV-2 virus. Another antibody, 1E10, exhibited different neutralization efficiency against SARS-CoV-2 and its variants, targeting a distinct epitope on the receptor-binding domain.
Article
Microbiology
Sarah Cherian et al.
Summary: Genomic epidemiology and whole genome sequencing were used to investigate the transmission and evolution of the SARS-CoV-2 virus during the global pandemic. The study identified new variants B.1.617.1 and B.1.617.2 in India, responsible for the second wave of COVID-19 in Maharashtra, with B.1.617.2 designated as a VOC delta and B.1.617.1 as a variant of interest kappa. Monitoring of these and emerging variants in India is crucial for public health.
Review
Microbiology
Edyta Janik et al.
Summary: Since the discovery of the SARS-CoV-2 responsible for COVID-19 in December 2019, the virus has continually mutated, with three variants of concern and four variants of interest being distinguished in recent months and requiring close monitoring.
Article
Medicine, General & Internal
Yaping Wang et al.
Summary: Infection with the Delta variant of concern (VOC) is characterized by a shorter incubation period, higher viral load, and longer duration of viral shedding, with an increased risk of critical illness for patients over the age of 60, calling for more intensive prevention and control measures.
Article
Medicine, General & Internal
Taufik Momin et al.
Summary: The Phase 1 trial of ZyCoV-D DNA vaccine conducted in India showed that the vaccine is safe, well-tolerated, and immunogenic, warranting further investigation.
Article
Medicine, General & Internal
Pablo Tebas et al.
Summary: The study found that the INO-4800 vaccine performed well in inducing immune responses and had good safety, with no serious adverse events reported. Participants exhibited both cellular and humoral immune responses to the vaccine, indicating its effectiveness in eliciting immunity.
Review
Medicine, Research & Experimental
Tomasz M. Karpinski et al.
Summary: The global outbreak of COVID-19 has emphasized the urgent need for effective vaccines and treatments. Advances in biotechnology and genetic engineering have provided progress in understanding the virus, with the development of vaccines being a key focus. Challenges in vaccine development and distribution, as well as the importance of safety and long-term effectiveness, have also been highlighted.
Review
Allergy
Peter L. Stern
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
(2020)
Article
Multidisciplinary Sciences
Rachel E. Baker et al.
Article
Biochemistry & Molecular Biology
Tyler N. Starr et al.
Article
Biochemistry & Molecular Biology
Qianqian Li et al.
Article
Biochemistry & Molecular Biology
Christopher O. Barnes et al.
Article
Biochemistry & Molecular Biology
Bette Korber et al.
Article
Biochemistry & Molecular Biology
Leonid Yurkovetskiy et al.
Article
Biochemistry & Molecular Biology
Luca Piccoli et al.
Article
Multidisciplinary Sciences
Davide F. Robbiani et al.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Article
Biochemistry & Molecular Biology
Seth J. Zost et al.
Article
Multidisciplinary Sciences
Alina Baum et al.
Article
Multidisciplinary Sciences
Hongjing Gu et al.
Article
Multidisciplinary Sciences
Johanna Hansen et al.
Article
Multidisciplinary Sciences
Meng Yuan et al.
Article
Multidisciplinary Sciences
Christopher O. Barnes et al.
Article
Medicine, General & Internal
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Medicine, General & Internal
E. J. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Medicine, General & Internal
Cheryl Keech et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Immunology
Hejun Liu et al.
Article
Multidisciplinary Sciences
Yufei Xiang et al.
Article
Biochemistry & Molecular Biology
Alexandra C. Walls et al.
Article
Biology
Yiska Weisblum et al.
Review
Biotechnology & Applied Microbiology
Giulietta Maruggi et al.
Article
Microbiology
Everett Clinton Smith et al.
Review
Biotechnology & Applied Microbiology
N Tatsis et al.
